FDA Signs Cooperative Agreement To Develop Standards For Warfarin-Dosing Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
The Critical Path Institute, in conjunction with the University of Utah, will be awarded $750,000 in funding by FDA to be used, in part, to validate and standardize genetic testing for biomarkers related to warfarin efficacy and metabolism.